Introduction: Significant advances have been made during the last two decades in terms of
new therapeutic options but also of innovative approaches to diagnosis and management of …

Recent years have witnessed a dramatic increase in the number of therapeutic options
available for the treatment of multiple myeloma (MM)-from immunomodulating agents to …

Multiple myeloma (MM) is a blood cell neoplasm characterized by excessive production of
malignant monoclonal plasma cells (activated B lymphocytes) by the bone marrow, which …

Introduction: Multiple myeloma (MM) is an incurable plasma cell malignancy, which causes
significant morbidity due to organ damage and bone tissue destruction. In recent years …

The past decade has witnessed a dramatic improvement in the therapeutic options in
multiple myeloma (MM). Several novel biologically targeted agents are in clinical use and …

Introduction: The development of proteasome inhibitor (PI) and immunomodulatory drugs
(IMiDs) and advances in supportive care have considerably changed the treatment …

Multiple myeloma remains an incurable disease despite numerous novel agents being
approved in the last decade. Furthermore, disease behavior and susceptibility to current …

Abstract Treatment in medical oncology is gradually shifting from the use of nonspecific
chemotherapeutic agents toward an era of novel targeted therapy in which drugs and their …

Introduction: Survival in multiple myeloma (MM) has improved significantly in the past 10
years due to new treatments, such as thalidomide and lenalidomide (immunomodulatory …

Multiple myeloma (MM) continues to evade cure by conventional therapies, increasing the
urgency for new, biologically based treatments. Reviewed in this discussion are novel …